JP2022514335A - コンジュゲート - Google Patents
コンジュゲート Download PDFInfo
- Publication number
- JP2022514335A JP2022514335A JP2021535300A JP2021535300A JP2022514335A JP 2022514335 A JP2022514335 A JP 2022514335A JP 2021535300 A JP2021535300 A JP 2021535300A JP 2021535300 A JP2021535300 A JP 2021535300A JP 2022514335 A JP2022514335 A JP 2022514335A
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- alkyl
- hydrogen
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)(C*)C(*)C(*(*)CCC(*I(C)N)=O)=O Chemical compound CC(*)(C*)C(*)C(*(*)CCC(*I(C)N)=O)=O 0.000 description 20
- AKRCNHIAVKDJTA-KTKRTIGZSA-N C/C(/C(N1)=Cc2ccc(CCCN)[n]2[B]1(F)F)=C/[IH]C Chemical compound C/C(/C(N1)=Cc2ccc(CCCN)[n]2[B]1(F)F)=C/[IH]C AKRCNHIAVKDJTA-KTKRTIGZSA-N 0.000 description 1
- HJQMJDHZGYNVBX-VOTSOKGWSA-N CC(C)(C)OC(/C=C/c1ccc[nH]1)=O Chemical compound CC(C)(C)OC(/C=C/c1ccc[nH]1)=O HJQMJDHZGYNVBX-VOTSOKGWSA-N 0.000 description 1
- PVZDCXNKIWOPQC-ONEGZZNKSA-N CC(C)(CC(N/C=C/C(O)=O)=O)CO Chemical compound CC(C)(CC(N/C=C/C(O)=O)=O)CO PVZDCXNKIWOPQC-ONEGZZNKSA-N 0.000 description 1
- HTHJHVIOGVKPPA-VOTSOKGWSA-N CC(C)(CC(N/C=C/C(OC)=O)=O)COC(C)(C)[O-] Chemical compound CC(C)(CC(N/C=C/C(OC)=O)=O)COC(C)(C)[O-] HTHJHVIOGVKPPA-VOTSOKGWSA-N 0.000 description 1
- AMQOQLKJHCZAAO-CMDGGOBGSA-N CC(C)(CC(N/C=C/C(OCc1ccccc1)=O)=O)CO Chemical compound CC(C)(CC(N/C=C/C(OCc1ccccc1)=O)=O)CO AMQOQLKJHCZAAO-CMDGGOBGSA-N 0.000 description 1
- WNYYRBFVQDTSAI-UHFFFAOYSA-N CC(C)(CC(NC=O)=O)COC(C)(C)[O-] Chemical compound CC(C)(CC(NC=O)=O)COC(C)(C)[O-] WNYYRBFVQDTSAI-UHFFFAOYSA-N 0.000 description 1
- HWKKTJQAKVPKTK-ARJAWSKDSA-N CC(C)(CO)C(C(N/C=C\C(O)=O)=O)O Chemical compound CC(C)(CO)C(C(N/C=C\C(O)=O)=O)O HWKKTJQAKVPKTK-ARJAWSKDSA-N 0.000 description 1
- IEXXJALTQLQWRT-QPBFKRLHSA-N CC(C)(CO)[C@H](C(N/C=C\C(NCCCN(C(C=C1)=O)C1=O)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(N/C=C\C(NCCCN(C(C=C1)=O)C1=O)=O)=O)O IEXXJALTQLQWRT-QPBFKRLHSA-N 0.000 description 1
- CSBPOVGJOMLDKS-YSRWOEIYSA-N CC/C=C(/C)\C(N1)=Cc2ccc(CCCNC(/C=C/NC(C3OC(C)(C)OCC3(C)C)=O)=O)[n]2[B]1(F)F Chemical compound CC/C=C(/C)\C(N1)=Cc2ccc(CCCNC(/C=C/NC(C3OC(C)(C)OCC3(C)C)=O)=O)[n]2[B]1(F)F CSBPOVGJOMLDKS-YSRWOEIYSA-N 0.000 description 1
- XGSNOPXWGWCWPB-UVTDQMKNSA-N CC1(C)C(C(N(C)/C=C\C#Cc2ccccc2)=O)OC(C)(C)OC1 Chemical compound CC1(C)C(C(N(C)/C=C\C#Cc2ccccc2)=O)OC(C)(C)OC1 XGSNOPXWGWCWPB-UVTDQMKNSA-N 0.000 description 1
- MTMIZEABQLGYRC-SOFGYWHQSA-N CC1(C)C(C(N/C=C/C(NCCCO)=O)=O)OC(C)(C)OC1 Chemical compound CC1(C)C(C(N/C=C/C(NCCCO)=O)=O)OC(C)(C)OC1 MTMIZEABQLGYRC-SOFGYWHQSA-N 0.000 description 1
- AJLIKIQNKKMMEC-AATRIKPKSA-N CC1(C)C(C(N/C=C/C(O)=O)=O)OC(C)(C)OC1 Chemical compound CC1(C)C(C(N/C=C/C(O)=O)=O)OC(C)(C)OC1 AJLIKIQNKKMMEC-AATRIKPKSA-N 0.000 description 1
- BXFIVQFYPPHJEM-WAYWQWQTSA-N CC1(C)C(C(N/C=C\Br)=O)OC(C)(C)OC1 Chemical compound CC1(C)C(C(N/C=C\Br)=O)OC(C)(C)OC1 BXFIVQFYPPHJEM-WAYWQWQTSA-N 0.000 description 1
- AJLIKIQNKKMMEC-WAYWQWQTSA-N CC1(C)C(C(N/C=C\C(O)=O)=O)OC(C)(C)OC1 Chemical compound CC1(C)C(C(N/C=C\C(O)=O)=O)OC(C)(C)OC1 AJLIKIQNKKMMEC-WAYWQWQTSA-N 0.000 description 1
- DTFUKXGTKJOCMI-YHWKNFMLSA-N CC1(C)[C@H](C(N/C=C\C(NCCCN(C(C=C2)=O)C2=O)=O)=O)OC(C)(C)OC1 Chemical compound CC1(C)[C@H](C(N/C=C\C(NCCCN(C(C=C2)=O)C2=O)=O)=O)OC(C)(C)OC1 DTFUKXGTKJOCMI-YHWKNFMLSA-N 0.000 description 1
- GWRPVTSLERQEPN-YVACAVLKSA-N CC1(C)[C@H](C(N/C=C\C(Oc(c(F)c(c(F)c2F)F)c2F)=O)=O)OC(C)(C)OC1 Chemical compound CC1(C)[C@H](C(N/C=C\C(Oc(c(F)c(c(F)c2F)F)c2F)=O)=O)OC(C)(C)OC1 GWRPVTSLERQEPN-YVACAVLKSA-N 0.000 description 1
- TXVLOQSELMMMNC-SFHVURJKSA-N CC1(C)[C@H](C(NCCC(NCCCCCN(C(C=C2)=O)C2=O)=O)=O)OC(C)(C)OC1 Chemical compound CC1(C)[C@H](C(NCCC(NCCCCCN(C(C=C2)=O)C2=O)=O)=O)OC(C)(C)OC1 TXVLOQSELMMMNC-SFHVURJKSA-N 0.000 description 1
- OCEGINYASHCCSQ-WUFSPUOTSA-N CCC(C)(C)[C@H]([C@@H](C)CC1)O[C@]1(C[C@H](C1)OC([C@@H]([C@@]([C@@H]2OC3)(/C3=C/C=C/[C@@H]3C)O)C=C(C)[C@H]2O[SiH-](C)(C)C(C)(C)C)=O)O[C@]1(C)C/C=C(\C)/[C@H]3/[O]=C(\C[C@@H]1OC)/O[C@@H](C)[C@@H]1O[C@@H](C[C@@H]1OC)O[C@@H](C)[C@@H]1O Chemical compound CCC(C)(C)[C@H]([C@@H](C)CC1)O[C@]1(C[C@H](C1)OC([C@@H]([C@@]([C@@H]2OC3)(/C3=C/C=C/[C@@H]3C)O)C=C(C)[C@H]2O[SiH-](C)(C)C(C)(C)C)=O)O[C@]1(C)C/C=C(\C)/[C@H]3/[O]=C(\C[C@@H]1OC)/O[C@@H](C)[C@@H]1O[C@@H](C[C@@H]1OC)O[C@@H](C)[C@@H]1O OCEGINYASHCCSQ-WUFSPUOTSA-N 0.000 description 1
- RKMOQLOKJZARIG-UHFFFAOYSA-N CCCSc(cc1)cc2c1[nH]c(N)n2 Chemical compound CCCSc(cc1)cc2c1[nH]c(N)n2 RKMOQLOKJZARIG-UHFFFAOYSA-N 0.000 description 1
- PFKINQXINHRVLL-UHFFFAOYSA-O Nc(cccc1)c1[NH2+]C=O Chemical compound Nc(cccc1)c1[NH2+]C=O PFKINQXINHRVLL-UHFFFAOYSA-O 0.000 description 1
- GTRDOUXISKJZGL-UHFFFAOYSA-N O=C(CNC1)N2C1c1ccccc1CC2 Chemical compound O=C(CNC1)N2C1c1ccccc1CC2 GTRDOUXISKJZGL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025007027A JP2025072404A (ja) | 2018-12-18 | 2025-01-17 | コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820626.8 | 2018-12-18 | ||
| GBGB1820626.8A GB201820626D0 (en) | 2018-12-18 | 2018-12-18 | Conjugates |
| PCT/EP2019/086120 WO2020127602A1 (en) | 2018-12-18 | 2019-12-18 | Conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025007027A Division JP2025072404A (ja) | 2018-12-18 | 2025-01-17 | コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514335A true JP2022514335A (ja) | 2022-02-10 |
| JP2022514335A5 JP2022514335A5 (cg-RX-API-DMAC7.html) | 2022-12-20 |
Family
ID=65147114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535300A Pending JP2022514335A (ja) | 2018-12-18 | 2019-12-18 | コンジュゲート |
| JP2025007027A Pending JP2025072404A (ja) | 2018-12-18 | 2025-01-17 | コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025007027A Pending JP2025072404A (ja) | 2018-12-18 | 2025-01-17 | コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220054658A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3897737A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022514335A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210106496A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113474007A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019400788A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021011860A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3123960A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201820626D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021006802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020127602A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685430B (zh) * | 2022-03-18 | 2023-07-21 | 浙江大学 | 芬苯达唑类似物及制备方法和应用 |
| WO2024049306A1 (en) * | 2022-08-31 | 2024-03-07 | Lopez Gonzalez Ricardo | Chemical conjugates, compositions, and methods of preparation and use thereof |
| CN120987848B (zh) * | 2025-07-10 | 2026-07-21 | 广州大学 | 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012064632A1 (en) * | 2010-11-12 | 2012-05-18 | Wake Forest University Health Sciences | Methods of treating cancer and other disorders |
| WO2012097454A1 (en) * | 2011-01-18 | 2012-07-26 | The Royal Institution For The Advancement Of Learning / Mcgill University | Compounds for use in the treatment of bacterial infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068485B1 (en) | 1981-07-01 | 1987-11-11 | Sanraku Incorporated | Novel antibiotics and process for production thereof |
| EP2370411A4 (en) * | 2008-12-05 | 2012-10-24 | Univ Oregon Health & Science | COMPOUNDS WITH ANTIPARASITIC OR ANTI-INFECTIOUS EFFECT |
| JP5852658B2 (ja) * | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| ES2907461T3 (es) * | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| WO2019060634A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
-
2018
- 2018-12-18 GB GBGB1820626.8A patent/GB201820626D0/en not_active Ceased
-
2019
- 2019-12-18 KR KR1020217022384A patent/KR20210106496A/ko not_active Ceased
- 2019-12-18 AU AU2019400788A patent/AU2019400788A1/en not_active Abandoned
- 2019-12-18 US US17/416,284 patent/US20220054658A1/en not_active Abandoned
- 2019-12-18 WO PCT/EP2019/086120 patent/WO2020127602A1/en not_active Ceased
- 2019-12-18 BR BR112021011860-8A patent/BR112021011860A2/pt unknown
- 2019-12-18 CA CA3123960A patent/CA3123960A1/en active Pending
- 2019-12-18 EP EP19829152.8A patent/EP3897737A1/en not_active Withdrawn
- 2019-12-18 JP JP2021535300A patent/JP2022514335A/ja active Pending
- 2019-12-18 CN CN201980092600.6A patent/CN113474007A/zh active Pending
- 2019-12-18 MX MX2021006802A patent/MX2021006802A/es unknown
-
2025
- 2025-01-17 JP JP2025007027A patent/JP2025072404A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012064632A1 (en) * | 2010-11-12 | 2012-05-18 | Wake Forest University Health Sciences | Methods of treating cancer and other disorders |
| WO2012097454A1 (en) * | 2011-01-18 | 2012-07-26 | The Royal Institution For The Advancement Of Learning / Mcgill University | Compounds for use in the treatment of bacterial infection |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201820626D0 (en) | 2019-01-30 |
| KR20210106496A (ko) | 2021-08-30 |
| JP2025072404A (ja) | 2025-05-09 |
| US20220054658A1 (en) | 2022-02-24 |
| WO2020127602A1 (en) | 2020-06-25 |
| EP3897737A1 (en) | 2021-10-27 |
| CA3123960A1 (en) | 2020-06-25 |
| MX2021006802A (es) | 2021-08-16 |
| AU2019400788A1 (en) | 2021-08-12 |
| CN113474007A (zh) | 2021-10-01 |
| BR112021011860A2 (pt) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025072404A (ja) | コンジュゲート | |
| JP7097880B2 (ja) | Malt1分解のための化合物 | |
| TW201741328A (zh) | 靶向組合物 | |
| CN105339351A (zh) | 精氨酸甲基转移酶抑制剂及其用途 | |
| EA022341B1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
| CN104011019B (zh) | 吡咯衍生物 | |
| CN104114547A (zh) | 呫吨酮化合物的衍生物 | |
| TW202342492A (zh) | 用於治療癌症之基於硫鏈絲菌肽之化合物及其製備 | |
| IL95956A (en) | Vaccines used to stop the growth and folding of VIH | |
| EA013244B1 (ru) | 8-МЕТОКСИ-9Н-ИЗОТИАЗОЛО[5,4-b]ХИНОЛИН-3,4-ДИОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОТИВОИНФЕКЦИОННЫХ СРЕДСТВ | |
| Nagel et al. | Efficient synthesis of (R)-harmonine–the toxic principle of the multicolored Asian lady beetle (Harmonia axyridis) | |
| JPWO1996033968A1 (ja) | 高水溶性メタロプロテイナーゼ阻害剤 | |
| CN106977506A (zh) | 二氢黄酮衍生物、其制备方法和用途 | |
| WO1996033968A1 (en) | Highly water-soluble metalloproteinase inhibitor | |
| JP7696301B2 (ja) | タンパク質分解のための化合物、組成物、および方法 | |
| JP7041129B2 (ja) | 抗感染剤 | |
| JP2025524721A (ja) | メタロトーシス関連障害の処置において使用するためのセロトニン類似体 | |
| TW202340207A (zh) | Klf2誘導劑及其使用方法 | |
| US20210040072A1 (en) | NTCP Inhibitors | |
| TW202506106A (zh) | 用於治療癌症之經修飾之硫鏈絲菌肽啟發之化合物及其製備 | |
| TW202525320A (zh) | 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物 | |
| CA2758103C (fr) | Peptides cycliques a activite antiparasitaire | |
| Karmakar et al. | Evaluating the leishmanicidal activity of m-Nitrocinnamic acid containing lipophilic peptide against leishmania donovani | |
| OA13294A (fr) | Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques. | |
| HK40111688A (en) | Inducers of klf2 and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240415 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240716 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240917 |